BioMarin Pharmaceutical Inc. (BMRN)
  • CONTENT
BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (BMRN)
Biomarin to File Regulatory Applications for Vosoritide in Q3
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
The 9 top biotech stocks to buy now to get through the coronavirus crisis, according to JPMorgan
In an April 3 research note, JPMorgan identified nine biotechnology companies they see as the best investment ideas for 2020. In past recessions, in 2001 and 2008-2009, the biotech industry outperformed the broader market. This time around, JPMorgan sees smaller biotechs facing a few big risks, such as disruptions to clinical trials and tightening liquidity for the capital markets. Here are the bank's top ideas of 2020 in the biotech industry. Visit Business Insider's homepage for more stories . As the coronavirus pandemic roils financial markets, JPMorgan analysts are highlighting the biotechnolgy industry as one space that has outperformed in past recessions. In 2008-2009, a leading biotech index outperformed by gaining 1% while the broader market dropped 23%. And in the 2001 recession, the analysts state that same biotech index held flat while the S&P 500 dropped 9%. This time around, biotech does face some heightened risks. Small companies that depend on clinical trials running on time and launching new drugs could face setbacks , because of the coronavirus overwhelming the healthcare system.
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) Arcus Biosciences Inc (NYSE: RCUS ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Centogene NV (NASDAQ: CNTG ) Cue Biopharma Inc (NASDAQ: CUE ) Forty Seven Inc (NASDAQ: FTSV ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Molecular Templates Inc (NASDAQ: MTEM ) Natera Inc (NASDAQ: NTRA ) Ocular Therapeutix Inc (NASDAQ: OCUL ) (Piper Sandler lifted the price target for the shares from $7 to $11) Quest Diagnostics Inc (NYSE: DGX ) (announced plans to launch a COVID-19 test service) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 5.) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Aytu Bioscience Inc (NASDAQ: AYTU ) Celcuity Inc (NASDAQ: CELC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) Glaukos Corp (NYSE: GKOS ) Lantheus Holdings Inc (NASDAQ: LNTH ) Mylan NV (NASDAQ: MYL ) Neurometrix Inc (NASDAQ: NURO ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Orthofix Medical Inc (NASDAQ: OFIX ) Passage Bio Inc (NASDAQ: PASG ) (went public last week) Polarityte Inc (NASDAQ: PTE ) STRATA Skin Sciences Inc (NASDAQ: SSKN ) SurModics, Inc. (NASDAQ: SRDX ) (reacted to first-quarter results) T2 Biosystems Inc (NASDAQ: TTOO ) Xeris …
The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) Acceleron Pharma Inc (NASDAQ: XLRN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Fate Therapeutics Inc (NASDAQ: FATE ) (reacted to its fourth-quarter results) Forty Seven Inc (NASDAQ: FTSV ) IGM Biosciences Inc (NASDAQ: IGMS ) Inovio Pharmaceuticals Inc (NASDAQ: INO )( announced an accelerated timeline for COVID-19 vaccine development) Repro-Med Systems, Inc. (NASDAQ: KRMD ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 3) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Midatech Pharma PLC-ADR (NASDAQ: MTP )(began trading on a reverse split adjusted basis) Mylan NV (NASDAQ: MYL ) Neuronetics Inc (NASDAQ: STIM )(announced its fourth-quarter results) Passage Bio Inc (NASDAQ: PASG )(IPOed last week) STRATA Skin Sciences Inc (NASDAQ: SSKN ) SurModics, Inc. (NASDAQ: SRDX ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TransMedics Group Inc (NASDAQ: TMDX )(reported its fourth-quarter results) VIVUS, Inc. (NASDAQ: VVUS ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Takeda To Develop COVID-19 Treatments Takeda Pharmaceutical Co Ltd (NYSE: TAK ) said it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin to treat high-risk individuals with the viral infection.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
/PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended…
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
SAN RAFAEL, Calif., Feb. 20, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for its investigational AAV5 gene therapy,…
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Follow Us